Answers are grounded in this paper and cite their sources.
Purpose: to evaluate the efficacy and safety of combined therapy with Photodynamic Therapy with Verteporfin (PDT-V) and ranibizumab same-day compared with monotherapy with ranibizumab (three monthly injections ) for the treatment of choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). of study : open-label, randomized controlled trial (RCT). and Methods: 17 eyes of 17 patients were consecutively enrolled and randomly assigned to ranibizumab intravitreal + PDT compared with a control group of 30 eyes of 30 patients treated with only ranibizumab 0.5mg in three monthly . Best corrected visual acuity (BCVA), central macular thickness (CMT) on optical coherence tomography were examined and after treatment. Patients were followed-up for twelve months. : in the combined therapy group, the mean baseline BCVA is 32.6 letters, at 24-months after treatment it’s 31.4 letters with loss of 1.2 letters. The mean central thickness at baseline is 314.6 μm. After twenty four months the mean CMT is 222.5 μm, mean CMT reduction of 92.1μm. In the ranibizumab-alone group, the mean baseline BCVA is 29.1 letters at 24-months it’s 28.6 letters with a little loss of 0.5 letters. The mean baseline CMT is 297.6 μm, at 24-months it is 235.9 μm, with mean CMT of 61,7μm. : the two treatments showed the same efficacy from a functional and anatomic point of view with a less number of in the combined therapy group. There were no serious ocular adverse events such as retinal detachment, endophthalmitis ocular hypertone.
No takes yet. Share an insight, caveat, or question.
Giustolisi et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: